Ribo Life Science-B (06938.HK) intends to acquire the remaining 49.71% equity interest in Ribocure Pharmaceuticals AB.

Zhitong Finance APP News, Ribo Life Science-B (06938.HK) announced that on October 16, 2026, the Company entered into a share exchange agreement with the minority shareholders, pursuant to which, subject to and in accordance with the terms and conditions of the share exchange agreement, the Company has conditionally agreed to acquire, and the minority shareholders have severally and conditionally agreed to sell, the target shares (representing in aggregate 49.71% of the total issued shares of the target company), such that the Company will hold the entire equity interest in the target company. As of the date of this announcement, the Company holds approximately 50.29% of the total issued shares of the target company. Upon completion, the target company will become a wholly-owned subsidiary of the Company.